A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas

Abroad (travel likely)RecruitingPHASE2

Conditions

Sarcoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

UHN- Princess Margaret Cancer Center, Toronto, Ontario, Canada
Contact: Study coordinator (Albiruni Razak, MD) · Albiruni.Razak@uhn.ca · 416 586 5371

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

Neuroblastoma · Rhabdomyosarcoma · Synovial Sarcoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Gainesville, United States

Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma

Osteogenic Sarcoma Recurrent

Abroad (travel likely)RecruitingPHASE2

Hackensack, United States · Houston, United States

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

Soft Tissue Sarcoma

Abroad (travel likely)RecruitingPHASE2

Houston, United States

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma

Kaposi Sarcoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States